Tranexamic Acid

The exact human tablet has sourced current registrations in Georgia and EU/EEA and an identifiable strength and manufacturer. It has no veterinary authorisation, and the assessed canine use is off-label.

Direct canine crossover data show oral absorption and reduced fibrinolysis in a laboratory model, but clinical outcome evidence is sparse and mixed. Trials of tranexamic acid in bleeding dogs have not consistently reduced transfusion, bleeding or survival outcomes, so oral use remains a selective adjunct rather than a proven routine therapy.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

A whole-only 500 mg tablet matches approximately 25-33 kg at the studied 15-20 mg/kg oral exposure, but is poorly measurable for many patients and the regimen may require dosing every 8 hours. Crushing does not validate an unmeasured powder fraction; use a measurable alternative for other doses.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Canine trials show pharmacodynamic suppression of hyperfibrinolysis, but clinical benefit is inconsistent: hemorrhagic-shock data showed clot effects without transfusion or survival benefit, and small ITP and haemorrhage studies did not establish routine outcome benefit. Use is therefore phenotype-selected and adjunctive.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 5 mL presentation requires venous access and slow IV administration but no complex reconstitution.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Feline evidence is limited to retrospective clinical use with varied regimens and uncertain causality. A 35-cat multicentre series found no standardized regimen and possible adverse events in 20%; canine mechanistic and outcome studies are indirect and cannot establish feline clinical benefit.

Published feline experience is small and reported possible adverse events in 20%, some severe, although causality was uncertain. Thrombosis, vomiting, hypotension with rapid IV delivery, renal accumulation, seizures and hypersensitivity remain clinically important concerns without a feline target-animal dossier.

The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 5 mL presentation requires venous access and slow IV administration but no complex reconstitution.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Canine trials show pharmacodynamic suppression of hyperfibrinolysis, but clinical benefit is inconsistent: hemorrhagic-shock data showed clot effects without transfusion or survival benefit, and small ITP and haemorrhage studies did not establish routine outcome benefit. Use is therefore phenotype-selected and adjunctive.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 10 mL presentation requires venous access and slow IV administration but no complex reconstitution.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Feline evidence is limited to retrospective clinical use with varied regimens and uncertain causality. A 35-cat multicentre series found no standardized regimen and possible adverse events in 20%; canine mechanistic and outcome studies are indirect and cannot establish feline clinical benefit.

Published feline experience is small and reported possible adverse events in 20%, some severe, although causality was uncertain. Thrombosis, vomiting, hypotension with rapid IV delivery, renal accumulation, seizures and hypersensitivity remain clinically important concerns without a feline target-animal dossier.

The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 10 mL presentation requires venous access and slow IV administration but no complex reconstitution.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Direct canine crossover data show oral absorption and reduced fibrinolysis in a laboratory model, but clinical outcome evidence is sparse and mixed. Trials of tranexamic acid in bleeding dogs have not consistently reduced transfusion, bleeding or survival outcomes, so oral use remains a selective adjunct rather than a proven routine therapy.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

A whole-only 500 mg tablet matches approximately 25-33 kg at the studied 15-20 mg/kg oral exposure, but is poorly measurable for many patients and the regimen may require dosing every 8 hours. Crushing does not validate an unmeasured powder fraction; use a measurable alternative for other doses.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Canine trials show pharmacodynamic suppression of hyperfibrinolysis, but clinical benefit is inconsistent: hemorrhagic-shock data showed clot effects without transfusion or survival benefit, and small ITP and haemorrhage studies did not establish routine outcome benefit. Use is therefore phenotype-selected and adjunctive.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 5 mL presentation requires venous access and slow IV administration but no complex reconstitution.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Feline evidence is limited to retrospective clinical use with varied regimens and uncertain causality. A 35-cat multicentre series found no standardized regimen and possible adverse events in 20%; canine mechanistic and outcome studies are indirect and cannot establish feline clinical benefit.

Published feline experience is small and reported possible adverse events in 20%, some severe, although causality was uncertain. Thrombosis, vomiting, hypotension with rapid IV delivery, renal accumulation, seizures and hypersensitivity remain clinically important concerns without a feline target-animal dossier.

The 100 mg/mL solution permits the sourced 10-15 mg/kg dose as 0.10-0.15 mL/kg with practical syringe accuracy in hospital. The 5 mL presentation requires venous access and slow IV administration but no complex reconstitution.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Direct canine crossover data show oral absorption and reduced fibrinolysis in a laboratory model, but clinical outcome evidence is sparse and mixed. Trials of tranexamic acid in bleeding dogs have not consistently reduced transfusion, bleeding or survival outcomes, so oral use remains a selective adjunct rather than a proven routine therapy.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

A whole-only 500 mg tablet matches approximately 25-33 kg at the studied 15-20 mg/kg oral exposure, but is poorly measurable for many patients and the regimen may require dosing every 8 hours. Crushing does not validate an unmeasured powder fraction; use a measurable alternative for other doses.

The exact human presentation has a sourced current Georgian registration and identifiable strength and manufacturer, but no exact trade-name registration was found in the exhaustively checked EU/EEA, UK or US registers. It has no veterinary authorisation and animal use is off-label.

Direct canine crossover data show oral absorption and reduced fibrinolysis in a laboratory model, but clinical outcome evidence is sparse and mixed. Trials of tranexamic acid in bleeding dogs have not consistently reduced transfusion, bleeding or survival outcomes, so oral use remains a selective adjunct rather than a proven routine therapy.

Short-course canine experience is usable but not benign: vomiting is dose- and rate-sensitive, and thrombosis, hypotension with rapid IV administration, renal accumulation, seizures and rare hypersensitivity require selection and monitoring. These exact human products have no canine target-animal safety dossier.

A whole-only 500 mg tablet matches approximately 25-33 kg at the studied 15-20 mg/kg oral exposure, but is poorly measurable for many patients and the regimen may require dosing every 8 hours. Crushing does not validate an unmeasured powder fraction; use a measurable alternative for other doses.